NEW YORK (GenomeWeb News) - Ciphergen Biosystems this week said it had no revenue in the first quarter of 2007, while R&D spending was down 23 percent and net loss improved by 12 percent.
The company also said its planned name change to Vermillion will take effect on Aug. 27, when it also will begin trading under the symbol VRML.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.